Skip to main content
Erschienen in: Annals of Nuclear Medicine 1/2017

29.09.2016 | Original Article

Diagnostic utility of a computer-aided diagnosis system for whole-body bone scintigraphy to detect bone metastasis in breast cancer patients

verfasst von: Misugi Urano, Yumi Maki, Hiroko Nishikawa, Tatsuya Kawai, Norio Shiraki, Yuta Shibamoto

Erschienen in: Annals of Nuclear Medicine | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Objective

To compare the diagnostic ability of planar images (PI) and images obtained by a computer-aided diagnosis (CAD) system (Viewer for Standardized Bone Scintigraphies; VSBONE) of whole-body bone scintigraphy for detecting bone metastases in breast cancer patients.

Methods

81 women (median: 56 years; range: 32–79) with a history of breast cancer were included in this study. They underwent whole-body bone scintigraphy after intravenous injection of 740 MBq technetium-99m hydroxymethylene diphosphonate. A total of 1066 bones (162 regions of the skull, 657 regions of the spine and pelvis, 223 regions of the sternum and rib, 18 regions of the upper extremities, and 6 regions of the lower extremities) were analyzed. The PI alone, VSBONE images alone, and both PI and VSBONE images (PI + VSBONE) were interpreted independently by two radiologists to diagnose bone metastases, which were then confirmed by magnetic resonance imaging. The sensitivity and specificity for each modality were analyzed using Fisher’s exact and McNemar tests. Inter-reviewer agreement was evaluated using a kappa statistic.

Results

Bone metastases were confirmed in 43 patients with 442 positive lesions. The average sensitivity of PI, VSBONE images, and PI + VSBONE images was 40.8, 50.2, and 61.8 %, respectively. The average specificity was 97.8, 97.5, and 97.6 %, respectively. The kappa scores were 0.62 for PI, 0.69 for VSBONE, and 0.77 for PI + VSBONE.

Conclusions

VSBONE was superior to PI in regard to sensitivity for detecting bone metastases in breast cancer patients. However, an improved CAD system is required to decrease the number of false-negative results.
Literatur
1.
Zurück zum Zitat Maffioli L, Florimonte L, Pagani L, Butti I, Roca I. Current role of bone scan with phosphonates in the follow-up of breast cancer. Eur J Nucl Med Mol Imaging. 2004;31:143–8.CrossRef Maffioli L, Florimonte L, Pagani L, Butti I, Roca I. Current role of bone scan with phosphonates in the follow-up of breast cancer. Eur J Nucl Med Mol Imaging. 2004;31:143–8.CrossRef
2.
Zurück zum Zitat Hayashi N, Yamauchi H, Nakamura S. Management of bone metastases from breast cancer. Gan To Kagaku Ryoho. 2012;39:1174–7.PubMed Hayashi N, Yamauchi H, Nakamura S. Management of bone metastases from breast cancer. Gan To Kagaku Ryoho. 2012;39:1174–7.PubMed
3.
Zurück zum Zitat Costa L. Bisphosphonates: reducing the risk of skeletal complications from bone metastasis. Breast. 2007;16:16–20.CrossRef Costa L. Bisphosphonates: reducing the risk of skeletal complications from bone metastasis. Breast. 2007;16:16–20.CrossRef
4.
Zurück zum Zitat Jeremic B, Shibamoto Y, Acimovic L, Milicic B, Milisavljevic S, Nikolic N, et al. A randomized trial of three single-dose radiation therapy regimens in the treatment of metastatic bone pain. Int J Radiat Oncol Biol Phys. 1998;42:161–7.CrossRefPubMed Jeremic B, Shibamoto Y, Acimovic L, Milicic B, Milisavljevic S, Nikolic N, et al. A randomized trial of three single-dose radiation therapy regimens in the treatment of metastatic bone pain. Int J Radiat Oncol Biol Phys. 1998;42:161–7.CrossRefPubMed
5.
Zurück zum Zitat Duo J, Han X, Zhang L, Wang G, Ma Y, Yang Y. Comparison of FDG PET/CT and gadolinium-enhanced MRI for the detection of bone metastases in patients with cancer: a meta-analysis. Clin Nucl Med. 2013;38:343–8.CrossRefPubMed Duo J, Han X, Zhang L, Wang G, Ma Y, Yang Y. Comparison of FDG PET/CT and gadolinium-enhanced MRI for the detection of bone metastases in patients with cancer: a meta-analysis. Clin Nucl Med. 2013;38:343–8.CrossRefPubMed
6.
Zurück zum Zitat Shen CT, Qiu ZL, Han TT, Luo QY. Performance of 18F-fluoride PET or PET/CT for the detection of bone metastases: a meta-analysis. Clin Nucl Med. 2015;40:103–10.CrossRefPubMed Shen CT, Qiu ZL, Han TT, Luo QY. Performance of 18F-fluoride PET or PET/CT for the detection of bone metastases: a meta-analysis. Clin Nucl Med. 2015;40:103–10.CrossRefPubMed
7.
Zurück zum Zitat Brennan ME, Houssami N. Evaluation of the evidence on staging imaging for detection of asymptomatic distant metastases in newly diagnosed breast cancer. Breast. 2012;21:112–23.CrossRefPubMed Brennan ME, Houssami N. Evaluation of the evidence on staging imaging for detection of asymptomatic distant metastases in newly diagnosed breast cancer. Breast. 2012;21:112–23.CrossRefPubMed
8.
Zurück zum Zitat Azad GK, Taylor B, Rubello D, Colletti PM, Goh V, Cook GJ. Molecular and functional imaging of bone metastases in breast and prostate cancers: an overview. Clin Nucl Med. 2016;41:e44–50.CrossRefPubMed Azad GK, Taylor B, Rubello D, Colletti PM, Goh V, Cook GJ. Molecular and functional imaging of bone metastases in breast and prostate cancers: an overview. Clin Nucl Med. 2016;41:e44–50.CrossRefPubMed
9.
Zurück zum Zitat Tokuda O, Harada Y, Ohishi Y, Matsunaga N, Edenbrandt L. Investigation of computer-aided diagnosis system for bone scans: a retrospective analysis in 406 patients. Ann Nucl Med. 2014;28:329–39.CrossRefPubMed Tokuda O, Harada Y, Ohishi Y, Matsunaga N, Edenbrandt L. Investigation of computer-aided diagnosis system for bone scans: a retrospective analysis in 406 patients. Ann Nucl Med. 2014;28:329–39.CrossRefPubMed
10.
Zurück zum Zitat Bombardieri E, Aktolun C, Baum RP, Bishof-Delaloye A, Buscombe J, Chatal JF, et al. Bone scintigraphy procedures guidelines for tumor imaging. Eur J Nucl Med Mol Imaging. 2003;30:107–14. Bombardieri E, Aktolun C, Baum RP, Bishof-Delaloye A, Buscombe J, Chatal JF, et al. Bone scintigraphy procedures guidelines for tumor imaging. Eur J Nucl Med Mol Imaging. 2003;30:107–14.
11.
Zurück zum Zitat Shiraishi J, Li Q, Appelbaum D, Pu Y, Doi K. Development of a computer-aided diagnostic scheme for detection of interval changes in successive whole-body bone scans. J Digit Imaging. 2011;24:680–7.CrossRefPubMed Shiraishi J, Li Q, Appelbaum D, Pu Y, Doi K. Development of a computer-aided diagnostic scheme for detection of interval changes in successive whole-body bone scans. J Digit Imaging. 2011;24:680–7.CrossRefPubMed
12.
Zurück zum Zitat Landis JR, Koch CG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:9–74. Landis JR, Koch CG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:9–74.
13.
Zurück zum Zitat Liu T, Cheng T, Xu W, Yan WL, Liu J, Yang HL. A meta-analysis of 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer. Skelet Radiol. 2011;40:523–31.CrossRef Liu T, Cheng T, Xu W, Yan WL, Liu J, Yang HL. A meta-analysis of 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer. Skelet Radiol. 2011;40:523–31.CrossRef
14.
Zurück zum Zitat Mitsui Y, Shiina H, Yamamoto Y, Haramoto M, Arichi N, Yasumoto H, et al. Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer. BJU Int. 2012;110:628–34.CrossRef Mitsui Y, Shiina H, Yamamoto Y, Haramoto M, Arichi N, Yasumoto H, et al. Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer. BJU Int. 2012;110:628–34.CrossRef
15.
Zurück zum Zitat Niikura N, Hashimoto J, Kazama T, Koizumi J, Ogiya R, Terao M, et al. Diagnostic performance of 18F-fluorodeoxyglucose PET/CT and bone scintigraphy in breast cancer patients with suspected bone metastasis. Breast Cancer. 2015. doi:10.1007/s12282-015-0621-z. Niikura N, Hashimoto J, Kazama T, Koizumi J, Ogiya R, Terao M, et al. Diagnostic performance of 18F-fluorodeoxyglucose PET/CT and bone scintigraphy in breast cancer patients with suspected bone metastasis. Breast Cancer. 2015. doi:10.​1007/​s12282-015-0621-z.
16.
Zurück zum Zitat Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-Fluoride PET, and 18F-Fluoride PET/CT. J Nucl Med. 2006;47:287–97.PubMed Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-Fluoride PET, and 18F-Fluoride PET/CT. J Nucl Med. 2006;47:287–97.PubMed
17.
Zurück zum Zitat Jambor I, Kuisma A, Ramadan S, Huovinen R, Sandell M, Kajander S, et al. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Acta Oncol. 2015;2:1–9. Jambor I, Kuisma A, Ramadan S, Huovinen R, Sandell M, Kajander S, et al. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Acta Oncol. 2015;2:1–9.
18.
Zurück zum Zitat Engelhard K, Hollenbach HP, Wohlfart K, von Imhoff E, Fellner FA. Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer. Eur Radiol. 2004;14:99–105.CrossRefPubMed Engelhard K, Hollenbach HP, Wohlfart K, von Imhoff E, Fellner FA. Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer. Eur Radiol. 2004;14:99–105.CrossRefPubMed
19.
Zurück zum Zitat Koizumi M, Miyaji N, Murata T, Motegi K, Miwa K, Koyama M, et al. Evaluation of a computer-assisted diagnosis system, BONENAVI version 2, for bone scintigraphy in cancer patients in a routine clinical setting. Ann Nucl Med. 2015;29:138–48.CrossRefPubMed Koizumi M, Miyaji N, Murata T, Motegi K, Miwa K, Koyama M, et al. Evaluation of a computer-assisted diagnosis system, BONENAVI version 2, for bone scintigraphy in cancer patients in a routine clinical setting. Ann Nucl Med. 2015;29:138–48.CrossRefPubMed
20.
Zurück zum Zitat Sharma P, Singh H, Kumar R, Bal C, Thulkar S, Seenu V, Malhotra A. Bone scintigraphy in breast cancer: added value of hybrid SPECT-CT and its impact on patient management. Nucl Med Commun. 2012;33:139–47.CrossRefPubMed Sharma P, Singh H, Kumar R, Bal C, Thulkar S, Seenu V, Malhotra A. Bone scintigraphy in breast cancer: added value of hybrid SPECT-CT and its impact on patient management. Nucl Med Commun. 2012;33:139–47.CrossRefPubMed
21.
Zurück zum Zitat Janicek MJ, Hayes DF, Kaplan WD. Healing flare in skeletal metastases from breast cancer. Radiology. 1994;192:201–4.CrossRefPubMed Janicek MJ, Hayes DF, Kaplan WD. Healing flare in skeletal metastases from breast cancer. Radiology. 1994;192:201–4.CrossRefPubMed
Metadaten
Titel
Diagnostic utility of a computer-aided diagnosis system for whole-body bone scintigraphy to detect bone metastasis in breast cancer patients
verfasst von
Misugi Urano
Yumi Maki
Hiroko Nishikawa
Tatsuya Kawai
Norio Shiraki
Yuta Shibamoto
Publikationsdatum
29.09.2016
Verlag
Springer Japan
Erschienen in
Annals of Nuclear Medicine / Ausgabe 1/2017
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-016-1132-5

Weitere Artikel der Ausgabe 1/2017

Annals of Nuclear Medicine 1/2017 Zur Ausgabe